NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (AMEX: PRW), a bio-pharmaceutical company developing proprietary polysaccharide-based therapeutic compounds in the treatment of cancer, today announced it has submitted clinical and pre-clinical data to the U.S. Food and Drug Administration (“FDA”) for a pre-Investigational New Drug (IND) meeting that is scheduled for October 8th. The Company plans to present the development plan to the FDA for an anti-hypoxia drug to be used in combination with DAVANAT® and 5-FU to treat advanced solid tumors, including head and neck, breast and colorectal cancers. The plan is in direct response to current studies indicating tumors resistance to chemotherapy and radiation are linked to hypoxia.
